Pharmaceutical Executive-03-01-2018

Features

March 20, 2018

Executives from diagnostics, payer, pharma, and patient care companies converge to share the inside scoop on outcomes-based contracting.

Pharmaceutical Executive
Features

March 19, 2018

Amid contrasting views on the success of the now well-established system of outcomes-based agreements in Italy, further demands on global healthcare budgets will likely point to their adoption on a wider scale

Pharmaceutical Executive
Features

March 16, 2018

Outcomes-based contracting could be a potential game changer in linking drug cost with value, boosting healthcare efficiency, and ensuring that appropriate patients benefit from innovative medicines. But several complex challenges remain in the bid to make this model a mainstay.

Pharmaceutical Executive

The public and policymakers seek more transparency in pricing and product development.

Pharmaceutical Executive

How one pharma vet helped create the first industry-wide training standards for aspiring medical affairs professionals. 

Pharmaceutical Executive
From the Editor

March 07, 2018

Tackling some of the unintended consequences associated with value-based contracting in pharma and efforts to advance toward sustainable outcomes-based engagement.

Pharmaceutical Executive
Features

March 07, 2018

Markus Warmuth, CEO of cancer genomics company H3 Biomedicine, speaks with Pharm Exec about being part of a new wave of biotech business leaders, who let the science chart the course.

Pharmaceutical Executive

Drawing from implementation lessons and successes in other industries, possible strategy shifts to pharma’s pricing playbook are explored.

Pharmaceutical Executive

Scope of supplementary protection certificate (SPC) could change.

Pharmaceutical Executive

Innovations in consumer genetic health are rapidly advancing-and pharma commercial thinking needs to catch up.

Pharmaceutical Executive
Special Sponsored Section

March 01, 2018

The global importance of the Indian pharmaceutical industry and the affordable generic drugs it produces is indisputable. But despite its evolving international role, India’s domestic healthcare system remains underperforming and undercapitalized.

Issue PDF
Pharmaceutical Executive

March 01, 2018

Click the title above to open the Pharmaceutical Executive March 2018 issue in an interactive PDF format.